AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Biotron Limited (ASX:BIT)
Bio Technological Company Biotron Limited (ASX:BIT) shares witnessed an intraday increase of 115 percent on 13 November 2018 after the company announced that its BIT225-009 HIV-1 Phase 2 data has been accepted for presentation at the upcoming HIV DART and Emerging Viruses 2018 meeting in the United States. Ever since the company released its results indicating that BIT225 is having a unique effect in patients, over and above viral suppression seen with current antiretroviral drugs, the share price of the company has been increasing rapidly. In the last three months, the shares of BIT increased by 525 percent as on 12 November 2018.Â
In the month of October, the company entered into an Option under writing agreement with CPS capital group, under which, the CPS Capital Group will underwrite any shortfall arising from 78,429,130 listed options exercisable at $0.06, with an expiry date of 30 November 2018. In FY 2018, the company reported an Operating loss before financing income of $1.61 million. The basic and diluted loss per share was 0.40 cents in FY 2018. During FY 2018, the current assets of the company decreased from $2.03 million in FY17 to $1.60 million. The net cash used in operating activities was $1.84 million in FY 2018. As the outlook for treatment of Hepatitis C virus (HCV) is particularly strong in emerging markets such as China, where an estimated 30 million people or more are infected with the virus. The company remains committed to identifying suitable partners and executing a China commercialization strategy. BITâs shares traded at $0.215 with a market capitalization of $54.53 million as on 13 November 2018 (AEST 4:00 PM).
PPK group Limited (ASX:PPK)
Mining Products manufacturer PPK group Limitedâs (ASX:PPK) shares increased by 28.125 percent in a single day after the company announced that it has signed a binding Heads of Agreement with one of Australiaâs leading technology incubator and commercialization companies, Australian Innovation Centre Pty Ltd (AIC), for the acquisition of 100% of AICIC. The company has further entered into Share Subscription Agreements to issue 9,100,000 PPK shares to Sophisticated Investors at $0.35 per share to raise $3,185,000. All capital raised will facilitate the funding of the AICIC acquisition.
During FY 2018, the total revenue of the company increased by 20 percent to $35.107 Million. The company incurred an overall loss of $1.561 million which was 379 percent less than the previous year. The company is expecting that the overall revenue growth in FY 2019 will be in the range of 15% to 25% and Net Profit Before Tax is expected to be in between $2.0M to $3.0M. With current assets of $17.403 million and no principal repayments of debt required to be made in the next financial year, PPK Group is in a strongest position to achieve better results in FY 2019.
PPK shares traded at $0.410 with a market capitalization of circa $19.84 million as on 13 November 2018 (AEST 4:00 PM).
Disclaimer
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.
Â
